Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ludwig, H; Spicka, I; Klener, P; Greil, R; Adam, Z; Gisslinger, H; Tarkovács, G; Linkesch, W; Maniatis, A; Morant, R; Drach, J; Kuhn, I; Schuster, J; Hinke, A.
Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
BRIT J HAEMATOL. 2005; 131(3): 329-337.
Doi: 10.1111/j.1365-2141.2005.05779.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We report on a randomised trial that aimed to compare the efficacy of continued daily prednisolone treatment during the entire induction phase, with prednisolone given for 2 weeks of each cycle in combination with VMCP (vincristine, melphalan, cyclophosphamide, prednisolone)-interferon-alpha 2b (IFN-alpha 2b) treatment in 299 previously untreated elderly patients (median age: 67 years) with multiple myeloma. After completion of induction treatment patients were randomised to IFN-alpha 2b with or without prednisolone, thrice weekly. Response rate was 62% in the continuous and 60% in the control arm (intent to treat analysis, P=0.81). Progression-free survival [median: 20 months vs. 19 months; hazard ratio (HR): 0.99, 95% confidence interval (CI): 0.74-1.33, P=0.97] and overall survival (median: 34 months vs. 37 months; HR: 1.16, 95% CI: 0.85-1.59, P=0.35) were similar in both groups. Reduced performance status (Eastern Cooperative Oncology Group, grades 2-4) was the predominant risk factor for poor survival followed by age >65 years, high beta2-microglobulin, and impaired renal function. There was more grades 3-4 dyspnoea and cardiac impairment and grades 1-2 hyperglycaemia, but less nausea, emesis and anaemia in patients on continuous prednisolone therapy. In conclusion, continuing prednisolone treatment during the entire duration of the induction phase with VMCP-IFN-alpha 2b did not improve outcome.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Combined Chemotherapy Protocols - administration and dosage
- Cyclophosphamide - administration and dosage
- Drug Administration Schedule - administration and dosage
- Female - administration and dosage
- Glucocorticoids - administration and dosage
- Humans - administration and dosage
- Interferon Alfa-2b - administration and dosage
- Male - administration and dosage
- Melphalan - administration and dosage
- Middle Aged - administration and dosage
- Multiple Myeloma - drug therapy
- Neoplasm Staging - drug therapy
- Prednisolone - administration and dosage
- Prednisone - administration and dosage
- Survival Analysis - administration and dosage
- Treatment Outcome - administration and dosage
- Vincristine - administration and dosage
- Find related publications in this database (Keywords)
- multiple myeloma
- continuous prednisolone
- VMCP-interferon therapy
- elderly patients
- randomised trial